For patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the New England Journal of Medicine.
May 31, 2023
0
6
Antidepressants lead to a small, but clinically unimportant, improvement in pain and function in patients with osteoarthritis, according to a review published online Oct. 21 in the Cochrane Library.
Nov 29, 2022
0
24
Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbVie.
Jun 20, 2022
0
4
A bivalent respiratory syncytial virus (RSV) prefusion F protein-based (RSVpreF) vaccine given during pregnancy elicits neutralizing antibody responses, according to a study published in the April 28 issue of the New England ...
Apr 28, 2022
0
2
The EU's medicines watchdog could start a review within days of an oral COVID drug produced by the US pharmaceutical firm Merck, a senior official said Tuesday.
Oct 5, 2021
0
13
(HealthDay)—For patients with moderately to severely active ulcerative colitis, ozanimod is more effective than placebo as induction and maintenance therapy, according to a study published in the Sept. 30 issue of the New ...
Sep 30, 2021
0
1
As concern has grown over COVID-19 variants and their implications for how well COVID-19 vaccines will protect against the virus, researchers have proposed a method to examine instances of SARS-COV-2 infections in people ...
Mar 25, 2021
0
5
Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease ...
Mar 2, 2021
0
7
Blood plasma from people recovering from COVID-19 could help prevent severe illness in older patients newly infected with the virus, a small new Argentinian study finds.
Jan 7, 2021
1
4
Hospitalised COVID-19 patients in the UK who received an inhaled form of interferon beta-1a (SNG001) were more likely to recover and less likely to develop severe symptoms than patients who received a placebo, according to ...
Nov 13, 2020
0
1
